2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

HHS-NIH-NIAID-BAA2026-1

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

NONE

Place of Performance

-

SourceSAM
Documents3
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), has released the 2027 NIAID DMID Omnibus Broad Agency Announcement (BAA), Solicitation No. HHS-NIH-NIAID-BAA2026-1. This solicitation seeks proposals to advance the development of medical interventions targeting infectious diseases, with a particular emphasis on addressing drug-resistant pathogens and aligning with national public health strategies such as the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan and CDC-identified antimicrobial resistance threats. The BAA is structured around three distinct research areas, each with specific objectives and deliverable expectations: **Research Area 001 – Vaccine Candidates:** This area solicits proposals for the development of vaccine candidates delivered via needle-free methods (i.e., alternatives to traditional needle and syringe) to protect against viral infections, including but not limited to respiratory and vector-borne viruses. The scope encompasses preclinical development, IND-enabling studies, limited process development, GMP-compliant manufacturing, regulatory submissions to the FDA, and the conduct of a Phase 1 or early Phase 2 clinical trial. Offerors must propose a single vaccine candidate targeting a specific viral pathogen, with the potential for broader protection against related viruses. Proposals must provide strong justification for the chosen antigen, platform, adjuvant (if applicable), and the clinical relevance of the needle-free delivery route. The inclusion of a clinical trial is mandatory. **Research Area 002 – Therapeutic Candidates:** This area focuses on the development of novel therapeutic products to improve outcomes for patients with serious infectious diseases lacking approved treatments or those refractory to existing therapies due to antimicrobial resistance. Target pathogens include viral hemorrhagic fever viruses (e.g., Ebola, Marburg, Lassa), encephalitic paramyxoviruses (e.g., Hendra, Nipah), picornaviruses (e.g., EV68, EV70, coxsackie virus), and a range of bacteria and fungi, including multidrug-resistant strains. Adjunct interventions that enhance antimicrobial effectiveness or address unresolved pathology post-pathogen clearance may also be considered. Eligible therapeutic candidates include advanced lead series, preclinical or clinical candidates such as small molecules, natural products, peptides, monoclonal antibodies, nanobodies, microbiome-based therapeutics, or bacteriophages. Supported activities range from lead optimization and preclinical IND-enabling studies to Phase 1 or proof-of-concept Phase 2 clinical trials. Preventative treatments are explicitly excluded from this research area. **Research Area 003 – In Vitro Diagnostics:** The objective here is to develop innovative diagnostic technology platforms capable of rapid detection and identification of a broad spectrum of viral pathogens, including those causing both acute and chronic infections. Preferred solutions will deliver actionable sequencing results within two hours directly from primary clinical specimens, feature nearly full automation, and support point-of-care configurations. Systems should process specimen volumes of 0.5–5 mL, recover analytes from low pathogen loads (10–100 genomic copies/mL), and achieve analytical sensitivity of 5–50 genome copies/mL. The platform should be reconfigurable to rapidly address novel pathogens and support multiple specimen throughput. Diagnostic systems must detect at least one, and preferably several, priority viral families, including Arenaviridae, Phenuviridae, Peribunyayviridae, Hantaviridae, Nairoviridae, Filoviridae, Flaviviridae, Paramyxoviridae, Togaviridae, and Picornaviridae. **Key Requirements and Considerations:** - Proposals must be submitted electronically via the NIAID eCPS website (https://ecps.nih.gov) by December 8, 2026, at 3:00 PM Eastern Time. Submissions by other methods are not permitted. - The BAA does not include any set-aside requirements; it is open to all qualified offerors. - Offerors are responsible for ensuring their proposals align with the detailed requirements and evaluation criteria outlined in the full BAA solicitation. - NIAID will not provide feedback or advice on specific technical approaches due to the competitive nature of the solicitation. - The BAA encourages alignment with NIH priorities, including enhancing rigor and reproducibility, improving biosafety and biosecurity, and utilizing non-animal testing methods where appropriate. **Contracting Entity and Contact Information:** - Contracting Entity: National Institutes of Health, NIAID, Division of Microbiology and Infectious Diseases (DMID) - Department: Department of Health and Human Services - NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology) - Product Service Code: AN12 - Primary Contact: Alexandra Buck, JD, Contracting Officer - Contact Email: [email protected] - Notice URL: [https://sam.gov/opp/b03314b0a1df4d9bb705526e20ff31b2/view](https://sam.gov/opp/b03314b0a1df4d9bb705526e20ff31b2/view) This BAA represents a significant opportunity for organizations with expertise in vaccine, therapeutic, or diagnostic development for infectious diseases to contribute to national and global health security. Contractors should carefully review the full solicitation for comprehensive requirements and ensure their proposed solutions are responsive to the outlined research areas and objectives.